Belotero Intense (+) Lidocaine Dermal Filler
Merz North America, Inc. · Decision date Oct 21, 2026
What did the FDA decide?
The FDA decision for supplement S006 to PMA P250016 covers a 30-day notice for Belotero Intense (+) Lidocaine dermal filler. The stated purpose is approval for modifications to the manual cleaning process for utensils and equipment used in manufacturing the product. The supplement type is a 30-day notice, and the reason is a process change involving manufacturer, sterilizer, packager, or supplier.
This notice does not represent a new approval of the dermal filler system itself. The decision field reads OK30, and the device is classified as an implant for aesthetic use under product code LMH. The source statement reports the intended process change but does not provide independent proof of safety or clinical effectiveness. Specific details about the cleaning modifications are absent from the supplied fields.
FDA approval order statement
Approval for modifications to the manual cleaning process for utensils and equipment used in the manufacture of Belotero Intense (+) Lidocaine dermal fillers.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 21, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250016/S006
- Regulatory pathway
- PMA supplement
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- Decision code
- OK30
- Decision date
- Oct 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250016 · Original PMA
Belotero Intense (+) Lidocaine
P250016/S006 received
Application receipt date recorded by FDA.
P250016/S006 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P250016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Merz North America, Inc. | PMA approval | Jul 9, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merz North America, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6501 Six Forks Rd., Raleigh, NC, 27615
Sources and methodology
- Original FDA record: P250016/S006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


